Tatsuro Yamamoto

Tatsuro Yamamoto

Auto-generated profile, based on publicly available information

Tatsuro Yamamoto

Genome Integrity Group, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1998 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
PDF file
MHMinoru Horisawa
Minoru Horisawa
JSJun Sasaki
Jun Sasaki
NNNoriji Niinomi
Noriji Niinomi
TYTatsuyoshi Yamamoto
Tatsuyoshi Yamamoto
TITakahiro Ito
Takahiro Ito

12 November 2024 in Science Signaling
Verified
Journal Article
Closed access
KWKenji Watanabe
Kenji Watanabe
TYTatsuro Yamamoto
Tatsuro Yamamoto
TFTomoko Fujita
Tomoko Fujita
SHShinjiro Hino
Shinjiro Hino
YHYuko Hino
Yuko Hino
NSNoriko Saitoh
Noriko Saitoh
Metabolic reprogramming from oxidative respiration to glycolysis is generally considered to be advantageous for tumor initiation and progression. However, we found that breast cancer cells forced to perform glycolysis acquired a vulnerability to PARP inhibitors. Small-molecule inhibition of mitochondrial respiration—using glyceollin I, metformin, or phenformin—induced overproduction of the oncometabolite lactate, which acidified the extracellular milieu and repressed the expression of homologous recombination (HR)–associated DNA repair genes. These serial events created so-called “BRCAness,” in which cells exhibit an HR deficiency phenotype despite lacking germline mutations in HR genes such as BRCA1 and BRCA2 , and, thus, sensitized the cancer cells to clinically available poly(ADP-ribose) polymerase inhibitors. The increase in lactate repressed HR-associated gene expression by decreasing histone acetylation. These effects were selective to breast cancer cells; normal epithelial cells retained HR proficiency and cell viability. These mechanistic insights into the BRCAness-prone properties of breast cancer cells support the therapeutic utility and cancer cell–specific potential of mitochondria-targeting drugs.

8 November 2025 in Cancer Letters
Verified
Journal Article
Open access
AFAlessandra Ferri
Alessandra Ferri
CCClaudia Contadini
Claudia Contadini
CGClaudia Di Girolamo
Claudia Di Girolamo
CCClaudia Cirotti
Claudia Cirotti
Giulia FisconGiulia Fiscon
Giulia Fiscon
DBDaniela Barilà
Daniela Barilà
Caspase-8 is a cysteine protease historically regarded as anti-neoplastic protein, thanks to its role in apoptosis. However, Caspase-8 expression is retained or even enhanced in several tumors, including glioblastoma (GBM), where it plays pro-tumor functions. We previously reported that it is a negative prognostic factor and contributes to resistance against DNA damaging agents, such as ionizing radiations (IR) and Temozolomide, commonly used in standard GBM treatment. We therefore investigated whether Caspase-8 may sustain DNA repair pathways proficiency in GBM. Here we uncover a novel role of Caspase-8 as promoter of the Homologous Recombination Repair (HRR). Importantly, IR promote Caspase-8 transient nuclear translocation and its recruitment to the chromatin. Moreover, Caspase-8 sustains the expression and the recruitment to the chromatin upon IR of RAD51 and CtIP, two key players of the HRR. Consistently, we identify a synthetically lethal interaction between Caspase-8 and PARP inhibition, that may enhance GBM sensitivity to IR. Remarkably, by using Caspase-8-/- murine embryo fibroblasts and a Drosophila melanogaster Caspase-8 mutant, we demonstrate that Caspase-8 plays an evolutionary conserved role in DNA repair.

4 June 2026 in Cell Death Discovery
Verified
Journal Article
Open access
TBTereza Buchtova
Tereza Buchtova
JBJirina Bartkova
Jirina Bartkova
TYTatsuro Yamamoto
Tatsuro Yamamoto
MBMarie Lund Bay
Marie Lund Bay
AJAllan Jensen
Allan Jensen
RSRobert Strauss
Robert Strauss
Tumor cell plasticity and stemness fuel treatment resistance and cancer evolution into often incurable, metastatic terminal disease. To better understand these fundamental aspects of tumorigenesis, here we examine a potential role of KCNMA1, a calcium-activated potassium channel that impacts cell (patho)physiology through membrane functions, in regulating ovarian cancer cell behavior, including plasticity, proliferation, mobility, and response to treatment. Pharmacological activation of KCNMA1 promoted differentiation, while channel blocking induced dedifferentiation and enhanced dissemination potential. Cyclical activation and inhibition potentiated the epithelial/mesenchymal hybrid cell state prone to stemness. KCNMA1 overexpression combined with low-dose channel blockade supported three-dimensional tumor growth. Mechanistically, we found that the balance between cytosolic calcium and potassium, in addition to their absolute levels, governed the observed changes. Our findings support a model in which KCNMA1-mediated regulation of potassium buffers fluctuating calcium signals that drive phenotypic plasticity, thereby stabilizing the epithelial/mesenchymal hybrid state. In addition, KCNMA1 modulation sensitized ovarian cancer cells to standard-of-care chemotherapeutics. Together, this work provides new insights into the role of KCNMA1 and calcium/potassium homeostasis in ovarian cancer cell adaptability, with implications for treatment.

23 January 2026 in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Verified
Journal Article
Open access
HNHibiki Nakamura-Yamada
Hibiki Nakamura-Yamada
YNYuka Nagao
Yuka Nagao
RYRyoji Yoshida
Ryoji Yoshida
HNHikaru Nakashima
Hikaru Nakashima
TYTatsuro Yamamoto
Tatsuro Yamamoto
HNHideki Nakayama
Hideki Nakayama

28 July 2026 in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Verified
Journal Article
Open access
TYTatsuro Yamamoto
Tatsuro Yamamoto
AHAkiyuki Hirosue
Akiyuki Hirosue
HNHonoka Nakayama
Honoka Nakayama
MNMasafumi Nakamoto
Masafumi Nakamoto
YNYuka Nagao
Yuka Nagao
HNHideki Nakayama
Hideki Nakayama